Factors related to rapid progression of non-small cell lung cancer in Chinese patients treated using single-agent immune checkpoint inhibitor treatment

Liang Zhang1,2, Lianwei Bai3, Xianhong Liu2, Ying Liu2, Shuang Li2, Jingjing Liu2, Shuang Zhang2, Changliang Yang2, Xiubao Ren1 & Ying Cheng2

1 Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer; Key Laboratory of Cancer Prevention and Therapy; Tianjin’s Clinical Research Center for Cancer; Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, China
2 Division of Thoracic Oncology, Jilin Cancer Hospital, Changchun, China
3 The Third Division of Medical Oncology, Jilin Cancer Hospital, Changchun, China

Keywords
Immune checkpoint inhibitor; non-small cell lung cancer; rapid progression.

Abstract
Background: Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of non-small cell lung cancer (NSCLC). While rapid progression (RP) has been proposed as a non-negligible pattern of response to ICIs, its definition and related factors remain unclear. This study aimed to develop a clinical definition of RP and to identify related factors.

Methods: We retrospectively evaluated Chinese patients who had received an ICI as second-line or later treatment for locally advanced or metastatic NSCLC at a single center. We defined RP as radiological progression at the first response assessment (<2 months after starting the ICI), as well as confirmation of progressive disease or cancer-related death occurring at <3 months. The clinical outcomes were compared for patients with RP or non-RP to identify prognostic factors.

Results: The study evaluated 74 eligible patients with detailed records regarding their ICI therapy, including 25 patients (33.8%) who had experienced RP. Relative to patients with non-RP, patients with RP had significantly shorter median progression-free survival (1.7 months [95% CI: 1.4–2.0 months] vs. 6.3 months [95% CI 5.2–7.3 months], P < 0.001; hazard ratio: 0.14, 95% CI: 0.08–0.25) and significantly shorter median overall survival (8.2 months [95% CI 3.0–13.4 months] vs. 22.6 months [95% CI 17.0–28.1 months], P < 0.001; hazard ratio: 0.27, 95% CI: 0.15–0.49). Multivariate analysis revealed that RP was independently predicted by the presence of ≥3 metastatic sites (P = 0.039) and a neutrophil-to-lymphocyte ratio of ≥3 (P = 0.044).

Conclusions: Among NSCLC patients, RP was a common response to ICI monotherapy and was associated with dramatically reduced progression-free and overall survival. Care is needed when selecting ICI monotherapy for these patients, especially if they have ≥3 metastatic sites or a neutrophil-to-lymphocyte ratio of ≥3.

Key points
Significant findings of the study: Patients with rapid progression after immune checkpoint inhibitor monotherapy had poor survival outcomes. The number of metastatic sites and the neutrophil-to-lymphocyte ratio may independently predict treatment response in this setting. What this study adds: This is the first study to evaluate rapid progression after second-line or later single-agent immunotherapy in a Chinese population. Our findings may help establish effective immunotherapy strategies for NSCLC.
Introduction

In the era of immuno-oncology, inhibitors of programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) have provided robust survival benefits for patients with locally advanced and metastatic non-small cell lung cancer (NSCLC). Single-agent nivolumab or atezolizumab treatments are now standard second-line treatments, regardless of PD-L1 status, as well as pembrolizumab for patients with a PD-L1 tumor proportion score of ≥1%. Pembrolizumab monotherapy is also approved as first-line treatment for advanced NSCLC in patients with PD-L1 expression of >50%, and this indication was recently extended to patients with PD-L1 expression of ≥1%.5,6

However, most NSCLC patients who receive single-agent immune checkpoint inhibitor (ICI) treatment do not experience antitumor activity in the second or later lines, with some patients even exhibiting a response pattern involving accelerated or rapid progression (RP). This phenomenon of accelerating tumor growth was also observed based on the early intersection of the progression-free survival (PFS) and overall survival (OS) curves with the initially inferior outcomes from several phase III trials of ICIs versus docetaxel for relapsed NSCLC. Hyperprogressive disease (HPD) resulting from immunotherapy has also been reported as a special response pattern. Nevertheless, the evaluation of HPD relies on the tumor growth rate or tumor growth kinetics, which requires multiple computed tomography (CT) scans. Thus, it can be complicated and inconvenient to apply this method of evaluating HPD in clinical practice. Furthermore, HPD does not include all patients who do not benefit from ICIs. Thus, RP has been suggested as a new potential alternative response pattern, although its definition and related factors remain unclear. This study aimed to develop a clinical definition of RP and to identify risk factors associated with this entity.

Methods

Study population

We retrospectively reviewed all patients who were hospitalized at Jilin Cancer Hospital between 1 March 2016 and 30 March 2019. The inclusion criteria were: a histologically confirmed diagnosis of NSCLC; stage IIIB or IV disease according to the American Joint Committee on Cancer guidelines (version 7); measurable disease according to version 1.1 of the Response Evaluation Criteria in Solid Tumors (RECIST v1.1); Eastern Cooperative Oncology Group (ECOG) performance status of ≤2; patients harboring EGFR mutations or ALK rearrangement were required to have previously received tyrosine kinase inhibitor (TKI) therapy and experienced disease progression; second-line or later ICI monotherapy (nivolumab, pembrolizumab, or atezolizumab); confirmation of response to the ICI; adequate organ function; and available clinical data. The key exclusion criteria were: no confirmation of treatment response and significant comorbidities or concurrent diseases that might influence the continuous administration of ICIs or lead to fatal clinical outcomes, such as active autoimmune disease, systemic immunosuppression, or unstable symptoms of brain metastasis.

Eligible patients received intravenous nivolumab at a dose of 3 mg/kg every two weeks, pembrolizumab at a fixed dose of 200 mg every three weeks, or atezolizumab at a fixed dose of 1200 mg every three weeks. Treatment continued until disease progression, discontinuation because of toxicity, or other reasons. Patients who received pembrolizumab required a PD-L1 tumor proportion score of ≥1%, while patients were allowed to receive nivolumab or atezolizumab regardless of PD-L1 expression. The ICIs could be continued after the initial determination of PD until the physician determined that the treatment provided no clinical benefit.

The study was conducted in accordance with good clinical practice guidelines and the declaration of Helsinki. The requirement for informed consent was waived based on the retrospective design.

Clinicopathological and laboratory data

The clinicopathological and laboratory data of patients were collected from their medical records. The present study considered age, sex, ECOG PS, smoking history, disease stage before ICI therapy, histological type, EGFR mutation or ALK rearrangement status, number and location of metastatic sites (lungs, liver, brain, bone, or adrenal gland), previous thoracic radiotherapy, previous therapy lines, tumor burden (measured as the sum of the unidimensional diameters of up to five target lesions per RECIST v1.1), PD-L1 expression, time since the last treatment, antibiotic use <2 months before starting ICIs, corticosteroid use <30 days before starting ICIs (equivalent to ≥10 mg of prednisone), the neutrophil-to-lymphocyte ratio (NLR) in peripheral blood, and serum lactate dehydrogenase (LDH) levels.

The response to ICI therapy was assessed based on RECIST v1.1, with responses defined as complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD). Response evaluations were generally performed every 6–8 weeks after starting ICI therapy, and involved imaging confirmation. The PFS interval was defined as the time from starting ICI treatment to the first instance of disease progression or death because of any
cause. The OS interval was defined as the time from starting ICI treatment to death because of any cause.

We considered RP present if there was radiological evidence of progression at the first response assessment (<two months after starting ICI treatment), with confirmation of PD occurrence or death because of disease progression within three months. Patients who did not fulfill the RP criteria were assigned to the nonrapid progression group (non-RP).

**Statistical analysis**

The RP and non-RP groups were compared to identify relevant prognostic factors. Univariable and multivariable Cox proportional hazard regression models were used to identify prognostic factors, and the results were reported as hazard ratios (HRs) with 95% confidence intervals (CIs). The OS and PFS curves were estimated using the Kaplan-Meier method and compared using the log-rank test. All reported P-values were two-sided, and P-values of <0.05 were considered statistically significant. All statistical analyses were performed using IBM SPSS software (version 25.0; IBM Corp., Armonk, New York).

**Results**

**Patient characteristics**

We identified 74 eligible patients who received single-agent ICI therapy as second-line or later treatment for locally advanced or metastatic NSCLC (Table 1). The ICI treatments involved nivolumab (50 patients, 67.6%), pembrolizumab (12 patients, 16.2%), and atezolizumab (12 patients, 16.2%). Immunohistochemistry-based testing for PD-L1 expression was performed for 39 patients, which revealed positive results (≥1% staining among the tumor cells) in 23 patients. All patients with adenocarcinoma underwent genetic testing for EGFR/ALK abnormalities, although this was not routinely performed for squamous cell carcinoma.

Based on our RP definition, we assigned 25 patients to the RP group (33.8%) and 49 patients to the non-RP group (66.2%).

**Clinical outcomes**

The median follow-up after starting ICI treatment was 14.1 months (95% CI: 1.7–39.3 months). At the time of the analysis, 64 patients (86.5%) had imaging-confirmed PD, and 44 patients had died (59.5%). The median overall PFS was 4.2 months (95% CI: 2.6–5.8 months) and the median overall OS was 16.8 months (95% CI: 12.5–21.0 months). The objective response rate (ORR) was 28.4% and the median duration of response (DOR) was 18.6 months (95% CI: 16.4–20.8 months).

We identified PD in 25 patients (100%) from the RP group and in 39 patients (79.6%) from the non-RP group. All eligible patients were evaluable for OS, with death observed for 22 patients (88.0%) in the RP group and for 22 patients (44.9%) in the non-RP group. The median PFS was 1.7 months in the RP group (95% CI: 1.4–2.0 months) and 6.3 months in the non-RP group (95% CI: 5.2–7.3 months, P < 0.001). The non-RP group had significantly better PFS (HR: 0.14, 95% CI: 0.08–0.25) (Fig 1a). The median OS was 8.2 months in the RP group (95% CI: 3.0–13.4 months) and 22.6 months in the non-RP group (95% CI: 17.0–28.1 months, P < 0.001). The non-RP group had significantly better OS (HR: 0.27, 95% CI: 0.15–0.49) (Fig 1b). Thus, the RP group experienced significantly poorer response to single-agent ICI treatment in terms of PFS and OS.

**Potential predictors of rapid progression**

Univariate and multivariate Cox regression analyses were performed to identify clinicopathological and laboratory factors that were associated with RP and survival (Table 2). The univariate analyses revealed that RP was not significantly associated with age, sex, smoking history, disease stage, histological type, metastatic site location, tumor burden, PD-L1 expression status, previous thoracic radiotherapy, previous therapy line, time since the last treatment, antibiotic or corticosteroid use before starting ICI treatment, or serum LDH levels. However, we found that RP was significantly associated with an ECOG PS of 2, genetic EGFR/ALK alterations, ≥3 metastatic sites, and a NLR of ≥3. These significant factors were included in the multivariate analyses.

The multivariate analyses revealed that RP was independently predicted by the patient having ≥3 metastatic sites (P = 0.039) and a NLR of ≥3 (P = 0.044), although no independent relationships were observed with an ECOG PS of 2 or genetic EGFR/ALK alterations. We observed a significant difference in OS between patients with <3 metastatic sites (19.8 months, 95% CI: 14.1–25.5 months) and patients with ≥3 metastatic sites (11.0 months, 95% CI: 5.9–16.1 months, P = 0.02). Fewer metastatic sites were associated with significantly better OS (HR: 0.50, 95% CI: 0.27–0.90) (Fig 2a). We also observed a significant difference in OS between patients with a NLR of <3 (23.1 months, 95% CI: 16.7–29.5 months) and patients with a NLR of ≥3 (10.5 months, 95% CI: 6.9–14.1 months, P = 0.002). A lower NLR was associated with significantly better OS (HR: 0.37, 95% CI: 0.20–0.70) (Fig 2b).
|                                | All patients N = 74 | Rapid progression N = 25 | Nonrapid progression N = 49 |
|--------------------------------|---------------------|-------------------------|-----------------------------|
| **Age (years)**                |                     |                         |                             |
| Median (range)                 | 62 (38–78)          | 60 (38–71)              | 62 (45–78)                  |
| ≥ 65 years                     | 21 (28.4%)          | 5 (20.0%)               | 16 (32.7%)                  |
| < 65 years                     | 53 (71.6%)          | 20 (80.0%)              | 33 (67.3%)                  |
| **Sex**                        |                     |                         |                             |
| Male                           | 56 (75.7%)          | 20 (80.0%)              | 36 (73.5%)                  |
| Female                         | 18 (24.3%)          | 5 (20.0%)               | 13 (26.5%)                  |
| **Smoking history**            |                     |                         |                             |
| Never                          | 31 (41.9%)          | 12 (48.0%)              | 19 (38.8%)                  |
| Current or former              | 43 (58.1%)          | 13 (52.0%)              | 30 (61.2%)                  |
| **Stage**                      |                     |                         |                             |
| IIIIB                          | 14 (18.9%)          | 4 (16.0%)               | 10 (20.4%)                  |
| IV                             | 60 (81.1%)          | 21 (84.0%)              | 39 (79.6%)                  |
| **Histology**                  |                     |                         |                             |
| Adenocarcinoma                 | 54 (73.0%)          | 17 (68.0%)              | 37 (75.5%)                  |
| Squamous                       | 20 (27.0%)          | 8 (32.0%)               | 12 (24.5%)                  |
| **ECOG PS**                    |                     |                         |                             |
| 0–1                            | 63 (85.1%)          | 18 (72.0%)              | 45 (91.8%)                  |
| 2                              | 11 (14.9%)          | 7 (28.0%)               | 4 (8.2%)                    |
| **EGFR/ALK mutational status**|                     |                         |                             |
| Positive                       | 12 (16.2%)          | 7 (28.0%)               | 5 (10.2%)                   |
| Negative                       | 42 (56.8%)          | 10 (40.0%)              | 32 (65.3%)                  |
| Missing                        | 20 (27.0%)          | 8 (32.0%)               | 12 (24.5%)                  |
| **Metastatic site**            |                     |                         |                             |
| Liver                          | 10 (13.5%)          | 4 (16.0%)               | 6 (12.2%)                   |
| Brain                          | 9 (12.2%)           | 4 (16.0%)               | 5 (10.2%)                   |
| Bone                           | 24 (32.4%)          | 8 (32.0%)               | 16 (32.7%)                  |
| Adrenal gland                  | 9 (12.2%)           | 4 (16.0%)               | 5 (10.2%)                   |
| Lung                           | 37 (50.0%)          | 12 (48.0%)              | 25 (51.0%)                  |
| **Number of metastatic sites** |                     |                         |                             |
| 0–2                            | 45 (60.8%)          | 11 (44.0%)              | 34 (69.4%)                  |
| ≥ 3                            | 29 (39.2%)          | 14 (56.0%)              | 15 (30.6%)                  |
| **Tumor burden**               |                     |                         |                             |
| < 10 cm                        | 59 (79.7%)          | 19 (76.0%)              | 40 (81.6%)                  |
| ≥ 10 cm                        | 15 (20.3%)          | 6 (24.0%)               | 9 (18.4%)                   |
| **Thoracic radiotherapy**      |                     |                         |                             |
| Yes                            | 16 (21.6%)          | 5 (20.0%)               | 11 (22.4%)                  |
| No                             | 58 (78.4%)          | 20 (80.0%)              | 38 (77.6%)                  |
| **Previous therapy lines**     |                     |                         |                             |
| 1                              | 49 (66.2%)          | 14 (56.0%)              | 35 (71.4%)                  |
| ≥ 2                            | 25 (33.8%)          | 11 (44.0%)              | 14 (28.6%)                  |
| **ICIs**                       |                     |                         |                             |
| Nivolumab                      | 50 (67.6%)          | 14 (56.0%)              | 36 (73.5%)                  |
| Pembrolizumab                  | 12 (16.2%)          | 7 (28.0%)               | 5 (10.2%)                   |
| Atezolizumab                   | 12 (16.2%)          | 4 (16.0%)               | 8 (16.3%)                   |
| **PD-L1 expression**           |                     |                         |                             |
| ≥ 1%                           | 23 (31.1%)          | 7 (28.0%)               | 16 (32.6%)                  |
| < 1%                           | 16 (21.6%)          | 9 (36.0%)               | 7 (14.3%)                   |
| Missing                        | 35 (47.3%)          | 9 (36.0%)               | 26 (53.1%)                  |
| **Receiving antibiotics < 2 months before ICIs** | | | |
| Yes                            | 12 (16.2%)          | 3 (12.0%)               | 9 (18.4%)                   |
| No                             | 62 (83.8%)          | 22 (88.0%)              | 40 (81.6%)                  |
| **Receiving corticosteroids < 30 days before ICIs** | | | |
| Yes                            | 12 (16.2%)          | 3 (12.0%)               | 9 (18.4%)                   |
| No                             | 62 (83.8%)          | 22 (88.0%)              | 40 (81.6%)                  |
Our findings suggest that the number of metastatic sites at baseline was associated with RP, which is consistent with a previous report that this factor is related to HPD.9 Our study also showed that RP was not associated with tumor burden, which is probably because the RECIST v1.1-defined target lesions do not always truly reflect the entire tumor burden, especially in patients with non-measurable disease, such as bone metastases, pleural effusion, or malignant atelectasis. Several studies have also shown that patients with high tumor burden experience poor OS after starting immunotherapy, which suggests that tumor burden may be a prognostic factor rather than a predictor of response.9,11

Another study has suggested that an age of >65 years was associated with hyperprogression,7 although conflicting results were observed in the present study and several other studies.8,9 Thus, we speculate that older age may not be a factor for excluding patients from receiving ICI therapy. Furthermore, we observed that RP was not associated with other baseline factors, including sex, disease stage, histological type, location of metastatic sites, thoracic radiotherapy, and time since the last treatment. Interestingly, we observed that an ECOG PS of two was associated with RP, but this association disappeared in the multivariate analysis. Thus, it remains unclear whether patients with a poor PS should receive ICI treatment, especially for patients who would not qualify for clinical trials.

Corticosteroids are commonly used to treat various complications in patients with advanced NSCLC. However, these drugs have immunosuppressive properties and may influence T cell function, which suggests that they may decrease the efficacy of immunotherapy.12 Moreover, baseline corticosteroid use equivalent to ≥10 mg of prednisone is associated with decreased ORR, PFS, and OS after starting ICI therapy.13 The gut microbiome was also recently shown to have direct effects on the innate and adaptive immune responses,14 with broad-spectrum antibiotic treatment adversely influencing the outcomes of ICI therapy through the modulation of the intestinal microbiota.15,16 A prospective study of 196 patients with NSCLC progression after ICI treatment

Table 1 Continued

| Time since the last treatment | All patients N = 74 | Rapid progression N = 25 | Nonrapid progression N = 49 |
|------------------------------|--------------------|-------------------------|--------------------------|
| < 6 months                   | 57 (77.0%)         | 18 (72.0%)              | 39 (79.6%)               |
| ≥ 6 months                   | 17 (23.0%)         | 7 (28.0%)               | 10 (20.4%)               |
| NLR ≥ 3                      | 42 (56.8%)         | 19 (76.0%)              | 23 (46.9%)               |
| NLR < 3                      | 32 (43.2%)         | 6 (24.0%)               | 26 (53.1%)               |
| LDH Normal                   | 57 (77.0%)         | 18 (72.0%)              | 39 (79.6%)               |
| LDH Elevated                 | 17 (23.0%)         | 7 (28.0%)               | 10 (20.4%)               |

ALK, anaplastic lymphoma kinase; ECOG PS, Eastern Cooperative Oncology Group performance status; EGFR, epidermal growth factor receptor; ICIs, immune checkpoint inhibitors; LDH, lactate dehydrogenase; NLR, neutrophil-to-lymphocyte ratio; PD-L1, programmed cell death ligand 1.
also concluded that antibiotic use before starting ICI therapy was associated with poorer rates of treatment response and survival. However, our findings suggest that corticosteroid or antibiotic use before ICI treatment was not related to RP. Thus, corticosteroids and antibiotics may potentially be useful if the need is urgent before starting ICI therapy, although further studies are needed regarding this subject.

The inflammation process may help explain immunoresistance in patients with cancer. The peripheral blood NLR and LDH levels may be potential inflammatory biomarkers in patients with cancer, and elevated values in several cancer types are associated with poor outcomes. Our study indicated that a NLR of ≥3 independently predicted RP and was associated with poor survival, although LDH levels were not associated

Figure 1 Kaplan-Meier curves for (a) progression-free-survival and (b) overall survival in patients with or without rapid progression. HR, hazard ratio; CI, confidence interval. (a) (---) Non-rapid progression and (---) rapid progression. (b) (---) Non-rapid progression and (---) rapid progression.

6.3 months vs. 1.7 months, P<0.001
HR: 0.14 (95% CI: 0.08–0.25)

22.6 months vs. 8.2 months, P<0.001
HR: 0.27 (95% CI: 0.15–0.49)
with RP or survival. Thus, the NLR may be a readily available prognostic factor for patients receiving ICIs. However, the NLR is a dynamic marker, and further studies are needed to determine whether changes in NLR during ICI treatment can help predict outcomes.

Approximately 50% of Chinese patients with adenocarcinoma have EGFR mutations, and this rate is significantly higher than among Caucasians. In this context, the use of ICIs remains controversial for patients harboring EGFR mutation and resistance to TKIs. Several studies have suggested that tumors with genetic EGFR/ALK alterations respond less well to ICI therapy than tumors without genetic EGFR/ALK alterations. The present study revealed that genetic EGFR/ALK alterations were associated with RP in the univariate analysis, although this association disappeared in the multivariate analysis. Nevertheless, the lack of an independent association could be related to the small size of this patient subgroup. A previous study has revealed an inverse relationship between PD-L1 expression and non-inflammatory tumor microenvironment. These features may explain poor outcomes after starting immunotherapy for patients with EGFR mutations. For example, the ATLANTIC study evaluated durvalumab in patients harboring EGFR/ALK mutations with TKI resistance, and revealed ORRs of 12.2% at PD-L1 expression of ≥25% and 3.6% at PD-L1 expression of <25%. Thus, the clinical activity of durvalumab was encouraging in EGFR-mutated tumors with PD-L1 expression of ≥25%. However, several phase III studies have revealed inconsistent relationships between PD-L1 expression level and the response to second-line ICI treatment. Our results also indicated that there was no significant relationship between PD-L1 expression and RP. We did not include the tumor mutational burden in the present study, because it is complex to evaluate and not routinely used in clinical practice. While a previous study has suggested that the tumor mutational burden may be associated with smoking, we found that smoking history did not predict RP in the present study.

The present study also has some important limitations. First, the retrospective single-center design and small sample size are associated with risks of bias. Second, further confirmation is needed regarding whether our definition of RP is feasible and practical. Third, additional studies are needed to further identify and validate factors that can predict the response to ICI treatment in patients with NSCLC.

In conclusion, we found that RP was a common response pattern to second-line or later single-agent ICI treatment for NSCLC, and that RP was associated with

| Table 2 | Univariate and multivariate analyses of factors associated with rapid progression |
|---|---|---|---|---|---|---|
| | HR (95% CI) | P-value | HR (95% CI) | P-value |
| Age (< 65 vs. ≥ 65 years) | 0.52 (0.16–1.62) | 0.258 | – | – |
| Sex (male vs. female) | 0.69 (0.22–2.23) | 0.537 | – | – |
| Smoking (never vs. current/former) | 1.46 (0.55–3.86) | 0.448 | – | – |
| Stage (IIIB vs. IV) | 0.74 (0.21–2.66) | 0.648 | – | – |
| Histology (adenocarcinoma vs. squamous) | 0.69 (0.24–2.00) | 0.493 | – | – |
| ECOG PS (0–1 vs. 2) | 0.23 (0.06–0.88) | 0.031 | 0.98 (0.54–2.47) | 0.213 |
| EGFR/ALK mutation (No vs. Yes) | 0.22 (0.06–0.86) | 0.029 | 0.80 (0.45–1.62) | 0.094 |
| Liver metastases (No vs. Yes) | 0.73 (0.19–2.88) | 0.656 | – | – |
| Brain metastases (No vs. Yes) | 0.60 (0.15–2.45) | 0.474 | – | – |
| Bone metastases (No vs. Yes) | 1.03 (0.37–2.89) | 0.955 | – | – |
| Adrenal gland metastases (No vs. Yes) | 0.60 (0.15–2.45) | 0.474 | – | – |
| Lung metastases (No vs. Yes) | 1.13 (0.43–2.96) | 0.806 | – | – |
| Metastatic sites (< 3 vs. ≥ 3) | 0.35 (0.13–0.94) | 0.037 | 0.59 (0.46–0.78) | 0.039 |
| Tumor burden (< 10 vs. ≥ 10 cm) | 0.71 (0.22–2.29) | 0.570 | – | – |
| PD-L1 expression (positive vs. negative) | 0.34 (0.09–1.28) | 0.112 | – | – |
| Previous therapy lines (1 vs. 2) | 0.49 (0.18–1.34) | 0.165 | – | – |
| Receiving antibiotics (No vs. yes) | 0.61 (0.15–2.47) | 0.485 | – | – |
| Receiving corticosteroid (No vs. yes) | 0.61 (0.15–2.47) | 0.485 | – | – |
| Time since the last treatment (< 6 vs. ≥ 6 months) | 0.66 (0.22–2.01) | 0.464 | – | – |
| NLR (< 3 vs. ≥ 3) | 0.28 (0.10–0.82) | 0.020 | 0.34 (0.12–0.97) | 0.044 |
| LDH (normal vs. elevated) | 0.66 (0.22–2.01) | 0.464 | – | – |

ALK, anaplastic lymphoma kinase; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; EGFR, epidermal growth factor receptor; HR, hazard ratio; LDH, lactate dehydrogenase; NLR, neutrophil-to-lymphocyte ratio; PD-L1, programmed cell death ligand 1.
significantly decreased PFS and OS. These findings may help guide the use of immunotherapy for NSCLC in routine clinical practice. For example, care is needed when selecting ICI monotherapy for NSCLC patients with risk factors for RP, and further studies are needed to better understand the mechanism of RP in patients with NSCLC.

**Acknowledgments**

This study was not supported by any specific funding.

**Disclosure**

The authors declare that there are no conflicts of interest.
References

1. Brahmer J, Reckamp KL, Baas P et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. *N Engl J Med* 2015; 373: 123–35.
2. Borghaei H, Paz-Ares L, Horn L et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. *N Engl J Med* 2015; 373: 1627–39.
3. Rittmeyer A, Barlesi F, Waterkamp D et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): A phase 3, open-label, multicenter randomized controlled trial. *Lancet* 2017; 389: 255–65.
4. Herbst RS, Baas P, Kim DW et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomized controlled trial. *Lancet* 2016; 387: 1540–50.
5. Reck M, Rodriguez-Abreu D, Robinson AG et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. *N Engl J Med* 2016; 375: 1823–33.
6. Mok TSK, Wu YL, Kudaba I et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): A randomised, open-label, controlled, phase 3 trial. *Lancet* 2019; 393: 1819–30.
7. Champiat S, Derle C, Ammari S et al. Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1. *Clin Cancer Res* 2017; 23: 1920–8.
8. Saâda-Bouzid E, Defauchex C, Karabajakian A et al. Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. *Ann Oncol* 2017; 28: 1605–11.
9. Ferrara R, Mezquita L, Texier M et al. Hyperprogressive disease in patients with advanced non-small cell lung cancer treated with PD-1/PD-L1 inhibitors or with single-agent chemotherapy. *JAMA Oncol* 2018; 4: 1543–52.
10. Brahmer J, Borghaei H, Ramalingam SS et al. Long-term survival outcomes with nivolumab in patients with previously treated advanced non-small cell lung cancer: Impact of early disease control and response. *AACR* 2019; Abstract CT195.
11. Sakata Y, Kawamura K, Ichikado K et al. Comparisons between tumor burden and other prognostic factors that influence survival of patients with non-small cell lung cancer treated with immune checkpoint inhibitors. *Thorac Cancer* 2019; 10: 2259–66.
12. Libert C, Dejager L. How steroids steer T cells. *Cell Rep* 2014; 7: 938–9.
13. Arbour KC, Mezquita L, Long N et al. Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer. *J Clin Oncol* 2018; 36: 2872–8.
14. Abt MC, Osborne LC, Monticelli LA et al. Commensal bacteria calibrate the activation threshold of innate antiviral immunity. *Immunity* 2017; 37: 158–70.
15. Derosa L, Hellmann MD, Spaziano M et al. Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer. *Ann Oncol* 2018; 29: 1437–44.
16. Weber D, Hieregeist A, Weber M et al. Detrimental effect of broad-spectrum antibiotics on intestinal microbiome diversity in patients after allogeneic stem cell transplantation: Lack of commensal sparing antibiotics. *Clin Infect Dis* 2019; 68: 1303–10.
17. Pinato DJ, Howlett S, Ottaviani D et al. Association of prior antibiotic treatment with survival and response to immune checkpoint inhibitor therapy in patients with cancer. *JAMA Oncol* 2019; 5: 1774. https://doi.org/10.1001/jamaoncol.2019.2785.
18. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. *Cell* 2011; 144: 646–74.
19. Mezquita L, Auclain E, Ferrara R et al. Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer. *JAMA Oncol* 2018; 4: 351–7.
20. Bagley SJ, Kothari S, Aggarwal C et al. Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer. *Lung Cancer* 2017; 106: 1–7.
21. Saddalan DB, Lucero J, Saddalan DL. Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: A review and meta-analysis. *Onco Targets Ther* 2018; 11: 955–65.
22. Weide B, Martens A, Hassel JC et al. Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab. *Clin Cancer Res* 2016; 22: 5487–96.
23. Gou LY, Wu YL. Prevalence of driver mutations in non-small-cell lung cancers in the People’s Republic of China. *Lung Cancer* 2014; 5: 1–9.
24. Gainor JF, Shaw AT, Sequist LV et al. EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: A retrospective analysis. *Clin Cancer Res* 2016; 22: 4585–93.
25. Byliccki O, Paleiron N, Margery J et al. Targeting the PD-1/PD-L1 immune checkpoint in EGFR-mutated or ALK-translocated non-small-cell lung cancer. *Target Oncol* 2017; 12: 563–9.
26. Lee CK, Man J, Lord S et al. Checkpoint inhibitors in metastatic EGFR-mutated non-small cell lung cancer-a meta-analysis. *J Thorac Oncol* 2017; 12: 403–7.
27. Ji M, Liu Y, Li Q et al. PD-1/PD-L1 expression in non-small-cell lung cancer and its correlation with EGFR/KRAS mutations. *Cancer Biol Ther* 2016; 17: 407–13.
28 Dong ZY, Zhang JT, Liu SY et al. EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer. *Oncoimmunology* 2017; 6: e1356145.

29 Garassino MC, Cho B-C, Kim JH et al. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): An open-label, single-arm, phase 2 study. *Lancet Oncol* 2018; 19: 521–36.

30 Spigel DR, Schrock AB, Fabrizio D et al. Total mutation burden (TMB) in lung cancer (LC) and relationship with response to PD-1/PD-L1 targeted therapies. *J Clin Oncol* 2016; 34: 9017.